EarlySight | Seed round closing
Share this article
1st closing round of CHF 2.3 million
EarlySight is delighted to announce the first closing of CHF 2.3 million out of a CHF 3 million seed funding round.
The start-up, which was founded in March 2019, uses a novel approach to provide a single cell level imaging of the back of the eye, called the retina. Its technology combines hardware and software to propose a unique medical device that can observe the cells affected at early-stage of the most prevalent retinal diseases such as age-related-macular degeneration (196 m people affected worldwide), glaucoma (76 m people affected worldwide) or diabetic retinopathy (95 m people affected worldwide), to treat them sooner and more efficiently. Coming out of the Laboratory of Applied Photonics Devices at EPFL, the startup has worked in close collaboration with Jules-Gonin eye hospital and Prof MD Francine Behar-Cohen to obtain the first clinical results on patients.
The funds will allow EarlySight to grow the team, optimise its technology and perform additional clinical validations. Thanks to them, important milestones will be reached to prepare the company for market entry.